Faculty

Statement of Need

Psoriatic arthritis (PsA) is a serious and potentially disabling condition that affects approximately 30% of psoriasis patients. In addition to the physical and functional impairments from joint destruction, PsA also negatively impacts relationships, daily activities, work productivity, and overall quality of life. Several agents have been FDA-approved for the treatment of moderate-to-severe PsA since 2008, and there are still more currently under investigation. Digital health tools provide clinicians with multiple touchpoints and reminders; they can help reinforce SMART goals, provide tips, and link to additional resources. Despite the availability of effective PsA agents, clinicians are often not aware of new and pipeline agents for their patients with moderate-to-severe PsA. Often, clinicians are not implementing newer agents or digital health tools into clinical practice that lead to better patient outcomes.

In this CME Outfitters Live and On Demand expert faculty will highlight the molecular targets of currently available and emerging biologic treatments for managing PsA, discuss individualized treatment plans, and provide updates on the latest clinical trials focused on the impact of long-term treatment, improving pain, and quality of life.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Identify the molecular targets of currently available and emerging biologic treatments for the management of PsA.
• Develop individualized treatment plans for patients with PsA that weigh the risks and benefits of newer agents.
• Evaluate recent clinical trial data regarding the impact of long-term treatment on improving pain and quality of life.

The following learning objectives pertain only to those requesting CNE or CPE credit:

• Identify the molecular targets of currently available and emerging biologic treatments for the management of PsA.
• Describe individualized treatment plans for patients with PsA that weigh the risks and benefits of newer agents.
• Evaluate recent clinical trial data regarding the impact of long-term treatment on improving pain and quality of life.

Financial Support

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Target Audience

Rheumatologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with psoriatic arthritis.

Credit Information

CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

USF Health designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with their participation in this activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology.  Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit^TMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)^TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-18-018-L01-P
Enduring: 0376-0000-18-018-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity
Enduring material

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit^TM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST27399 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibofsky reports that he is on the Speakers Bureau for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc.; and Pfizer, Inc. He is a consultant for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Samumed, LLC; and Sandoz. He is a stock shareholder of AbbVie Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.

Dr. Gelfand reports that he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie Inc.; Celgene Corporation; Janssen Biologics, Inc.; Novartis Corporation, Pfizer Inc.; Ortho Dermatologics, Inc.; and Sanofi. He is a consultant for Bristol-Myers Squibb Company; Boehringer Ingelheim; GlaxoSmithKline; Janssen Biologics, Inc.; Novartis Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and UCB Data and Safety Monitoring Board (DSMB). He received other financial or material support as a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.